GlaxoSmithKline Extends Use of InforSense Platform | GenomeWeb
NEW YORK (GenomeWeb News) – InforSense said on Friday that GlaxoSmithKline has signed a contract to continue using the firm’s InforSense platform for another three years.
The London-based firm said that around 800 users within the drug giant are currently using the platform, which is a workflow-management software tool.
Terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.